H19 (H19 Imprinted Maternally Expressed Transcript)

Correlation and regression analyses validated the proposed ceRNA interactions and their significant association with advanced cancer stage. A high-risk score from the H19/miR-152/DNMT1 axis was prognostic only in thyroid cancer (HR = 2.97).

The complexity of H19 functions in the liver is reflected in its interaction and regulation of a growing number of proteins, and coding and non-coding RNAs involved in metabolism, pro-fibrotic gene networks, cell cycle progression, and chromatin regulation. This review summarizes the findings related to the role of H19 in liver development and in diseases such as fatty liver, fibrosis, and hepatocellular carcinoma.

Functional assays demonstrated that FAM117A and PIGU regulate the p53 signaling pathway and modulate cell adhesion molecules (N-cadherin and E-cadherin), highlighting their involvement in abnormal proliferation and tumor metastasis during GC progression. These findings identify FAM117A and PIGU as novel biomarkers and potential therapeutic targets, providing mechanistic insights into gastric carcinogenesis.

Our findings suggest that H19 might play a role in STS pathogenesis. While its prognostic value requires further investigation, H19-based targeting approaches may warrant evaluation for therapeutic potential in STS.

Infants with macrosomia, macroglossia, and umbilical hernia should be evaluated for BWS. Long-term multidisciplinary follow-up, including tumor surveillance and cardiac monitoring, is essential for improving prognosis and quality of life.

Overall, these findings deepen our understanding of the molecular changes linked to high-risk HPV infections and identify PI3K, MALAT1 and H19 as promising biomarkers and therapeutic targets for cervical cancer. Future studies should further investigate these interactions to enhance early detection and improve treatment strategies for HPV-associated malignancies.

We highlight, as a specific result, that a panel of lncRNAs (e.g., H19, NEAT1, OIP5-AS, MALAT1) and miRNAs (e.g., miR-21, miR-92a) have been consistently validated with excellent diagnostic accuracy and are strongly associated with poor overall survival. According to our findings, these computationally generated ncRNA signatures are practical tools for GIC prognosis and early diagnosis, opening the door for their incorporation into personalized oncology.

Collectively, these findings identify METTL3-mediated m6A modification of H19 as a critical suppressor of ICCA progression through modulation of PPARγ signaling. One interesting treatment option for ICCA may be the use of H19-armed oncolytic adenoviruses, especially when combined with PPARγ suppression.

The specificity of H19 expression in OSCC compared to normal presents an attractive target for cancer-specific therapies, minimizing the risk of off-target effects.

New technologies, including single-cell RNA sequencing and spatial transcriptomics, will improve understanding of heterogeneous lncRNA-microRNA networks in TC and support precision medicine. LncRNAs signify both molecular drivers and clinical targets for thyroid cancer.

These interconnected circuits offer novel insights into treatment resistance and stem cell persistence, identifying promising therapeutic targets. Future validation of these interactions may guide the development of non-coding RNA-targeted therapies for resistant CML.

Furthermore, lncRNAs are implicated in DNA damage and genomic instability induced by H. pylori, as well as in creating the tumor microenvironment by regulating angiogenesis and immune evasion. This multifaceted involvement positions lncRNAs as promising diagnostic, prognostic, and therapeutic markers for H. pylori-associated GC, warranting further investigation for novel clinical interventions.